Executive Summary

Highlights at this year’s 19th Conference on Retroviruses and Opportunistic Infections (CROI) included additional data from Gilead’s ELECTRON trial (GS-7977, formerly known as PSI-7977) focusing on patients with genotype 1 hepatitis C and top line data from Sangamo Biosciences’ SB-728-T HIV program including results from the phase 1 902 study and the phase 2 902, Cohort 5 extension study. To discuss these and other updates on hepatitis C and HIV therapies, GLG Research hosted a panel teleconference live from the conference.

Classified In

Healthcare